284 related articles for article (PubMed ID: 36883059)
1. Dense GM-CSFR
Saranaruk P; Waraasawapati S; Chamgramol Y; Sawanyawisuth K; Paungpan N; Somphud N; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
PeerJ; 2023; 11():e14883. PubMed ID: 36883059
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor.
Sasaki M; Tsuneyama K; Ishikawa A; Nakanuma Y
Hum Pathol; 2003 Dec; 34(12):1337-44. PubMed ID: 14691921
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation.
Cook AD; Louis C; Robinson MJ; Saleh R; Sleeman MA; Hamilton JA
Arthritis Res Ther; 2016 Dec; 18(1):287. PubMed ID: 27908288
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.
Ruffolo LI; Jackson KM; Kuhlers PC; Dale BS; Figueroa Guilliani NM; Ullman NA; Burchard PR; Qin SS; Juviler PG; Keilson JM; Morrison AB; Georger M; Jewell R; Calvi LM; Nywening TM; O'Dell MR; Hezel AF; De Las Casas L; Lesinski GB; Yeh JJ; Hernandez-Alejandro R; Belt BA; Linehan DC
Gut; 2022 Jul; 71(7):1386-1398. PubMed ID: 34413131
[TBL] [Abstract][Full Text] [Related]
6. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
7. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
8. Construction and binding kinetics of a soluble granulocyte-macrophage colony-stimulating factor receptor alpha-chain-Fc fusion protein.
Monfardini C; Ramamoorthy M; Rosenbaum H; Fang Q; Godillot PA; Canziani G; Chaiken IM; Williams WV
J Biol Chem; 1998 Mar; 273(13):7657-67. PubMed ID: 9516471
[TBL] [Abstract][Full Text] [Related]
9. Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival.
Thakral N; Gonzalez T; Nano O; Shin SH; Samuels S; Hussein A
BMC Gastroenterol; 2023 May; 23(1):151. PubMed ID: 37179301
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil GM-CSF receptor dynamics in acute lung injury.
De Alessandris S; Ferguson GJ; Dodd AJ; Juss JK; Devaprasad A; Piper S; Wyatt O; Killick H; Corkill DJ; Cohen ES; Pandit A; Radstake TRDJ; Simmonds R; Condliffe AM; Sleeman MA; Cowburn AS; Finch DK; Chilvers ER
J Leukoc Biol; 2019 Jun; 105(6):1183-1194. PubMed ID: 30942918
[TBL] [Abstract][Full Text] [Related]
11. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
12. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
13. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
[TBL] [Abstract][Full Text] [Related]
14. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
15. The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation.
Matsuguchi T; Zhao Y; Lilly MB; Kraft AS
J Biol Chem; 1997 Jul; 272(28):17450-9. PubMed ID: 9211889
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
17. Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway.
Dana P; Kariya R; Lert-Itthiporn W; Seubwai W; Saisomboon S; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948304
[TBL] [Abstract][Full Text] [Related]
18. Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients.
Khunluck T; Kukongviriyapan V; Puapairoj A; Khuntikeo N; Senggunprai L; Zeekpudsa P; Prawan A
Asian Pac J Cancer Prev; 2014; 15(1):299-304. PubMed ID: 24528044
[TBL] [Abstract][Full Text] [Related]
19. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
20. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]